Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-αAlexis Mathian, Paul Breillat, Karim Dorgham, Paul Bastard, Caroline Charre, Raphael Lhote, Paul Quentric, Quentin Moyon, Alice-Andrée Mariaggi, Suzanne Mouries-Martin, Clara Mellot, François Anna, Julien Haroche, Fleur Cohen-Aubart, Delphine Sterlin
See the full list of authors10 November 2022
Dissecting the histological features of lupus nephritis highlights new common patterns of injury in class III/IVMaddalena Maria Bolognesi, Giulia Capitoli, Stefania Galimberti, Giorgio Cattoretti, Ingeborg Bajema, Jan A Bruijn, H Terence Cook, Laure-Helene Noel, Fabio Pagni, Franco Ferrario, Maria Wester Trejo, Vincenzo L'Imperio
10 November 2022
Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trialJens Y Humrich, Patrice Cacoub, Michelle Rosenzwajg, Fabien Pitoiset, Hang Phuong PHAM, Joel Guidoux, David Leroux, Thomas Vazquez, Gabriela Riemekasten, Josef S Smolen, George Tsokos, David Klatzmann
10 November 2022
Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosusLingxiao Xu, Jian Zhao, Qing Sun, Xue Xu, Lei Wang, Ting Liu, Yunjuan Wu, Jingfeng Zhu, Linyu Geng, Yun Deng, Alexander Awgulewitsch, Diane L Kamen, Jim C Oates, Prithvi Raj, Edward K Wakeland
See the full list of authors10 November 2022
Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling studyJingru Tian, Dingyao Zhang, Xu Yao, Yaqing Huang, Qianjin Lu
14 October 2022
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-upQiong Fu, Chunmei Wu, Min Dai, Suli Wang, Jianhua Xu, Lie Dai, Zhijun Li, Lan He, Xiaochun Zhu, Lingyun Sun, Liangjing Lu, Chunde Bao
12 October 2022
Pathogenic neuropsychiatric effect of stress-induced microglial interleukin 12/23 axis in systemic lupus erythematosusNobuya Abe, Masato Tarumi, Yuichiro Fujieda, Nobuhiko Takahashi, Kohei Karino, Mona Uchida, Michihito Kono, Yuki Tanaka, Rie Hasebe, Masaru Kato, Olga Amengual, Yoshiyuki Arinuma, Kenji Oku, Wakiro Sato, Khin Khin Tha
See the full list of authors12 October 2022
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosusRonald F van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, Bevra H Hahn, Yoshiya Tanaka, Robert M Gordon, Cathye Shu, Kaiyin Fei, Sheng Gao, Loqmane Seridi, Patrick Gallagher, Kim Hung Lo, Pamela Berry, Qing C Zuraw
12 October 2022
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohortManuel Francisco Ugarte-Gil, John Hanly, Murray Urowitz, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Ann Elaine Clarke, Daniel J Wallace, David Alan Isenberg, Anisur Rahman, Joan T Merrill, Paul R Fortin, Dafna D Gladman
See the full list of authors12 October 2022
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosusSarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, Jun Chu, Elaine Poncio, Mohammad Naqi, Sarthak Gupta, Xinghao Wang, Christopher Oliveira, Dillon Claybaugh, Amit Dey, Shajia Lu, Philip Carlucci, Monica Purmalek, Zerai G Manna
See the full list of authors12 October 2022
